MedTrace Logo

Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors

NCT02853903 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-09-12

No results posted yet for this study

Summary

The aim of this study is the efficacy of autogenic and allogenic natural killer (NK) immunotherapy on recurrent solid tumors.

Conditions

  • Malignant Solid Tumour

Interventions

BIOLOGICAL

NK immunotherapy

Each treatment: 8-10 billion cells in all, transfusion in 3 times, i.v.

Sponsors & Collaborators

  • Shenzhen Hank Bioengineering Institute

    collaborator OTHER

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Principal Investigators

  • Jibing Chen, MD, PhD · Fuda Cancer Hospital, Guangzhou

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-01
Primary Completion
2017-07-01
Completion
2019-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02853903 on ClinicalTrials.gov